Protalix BioTherapeutics (PLX) Return on Capital Employed (2011 - 2026)

Protalix BioTherapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 30.47% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 2109.0% year-over-year to 30.47% in Q1 2026; TTM through Mar 2026 was 30.47%, a 2109.0% increase from a year earlier, with the FY2025 full-year figure at 10.71%, down 1806.0% from the prior year.
• Return on Capital Employed climbed to 30.47% in Q1 2026 per PLX's latest filing, from 9.86% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 30.47% in Q1 2026 and bottomed at 66.57% in Q3 2022.
• The 5-year median for Return on Capital Employed is 9.36% (2024), against an average of 9.19%.
• Across the five-year window, Return on Capital Employed jumped 9700 bps in 2023 and tumbled 6790 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 54.64% in 2022, then soared by 147 bps to 25.85% in 2023, then slumped by 64 bps to 9.36% in 2024, then tumbled by 205 bps to 9.86% in 2025, then jumped by 409 bps to 30.47% in 2026.
• Per Business Quant, the three latest PLX Return on Capital Employed figures stand at 30.47% (Q1 2026), 9.86% (Q4 2025), and 10.9% (Q3 2025).